 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- Tysabri (natalizumab) / Biogen, Royalty
Targeting GPR183/oxysterol signalling in remyelination (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1054;
It is upregulated in MS plaques and in natalizumab treated MS patients... Pharmacological modulation of GPR183 signalling is a druggable target for remyelination therapy.